Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mélanie Wilbaux

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Expert Review of Clinical Pharmacology|November 5, 2016
Pharmacometrics-based decision tools facilitate mHealth implementationFahima Nekka, Chantal Csajka, Mélanie Wilbaux, et al.
Expert Opinion on Drug Metabolism & Toxicology|January 29, 2016
Quantitative clinical pharmacology practice for optimal use of antibiotics during the neonatal periodJanko Samardzic, Karel Allegaert, Mélanie Wilbaux, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|December 16, 2016
Characterizing the dynamic interaction among gastric emptying, glucose absorption, and glycemic control in nondiabetic obese adultsMélanie Wilbaux, Bettina K Wölnerhanssen, Anne Christin Meyer-Gerspach, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 21, 2022
Contribution of machine learning to tumor growth inhibition modeling for hepatocellular carcinoma patients under Roblitinib (FGF401) drug treatmentMélanie Wilbaux, David Demanse, Yi Gu, et al.
The Journal of Pediatrics|April 4, 2016
Characterizing and Forecasting Individual Weight Changes in Term NeonatesMélanie Wilbaux, Severin Kasser, Sven Wellmann, et al.
Clinical Pharmacology and Therapeutics|September 22, 2022
Integration of Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy into Model-Informed Dose Selection in Oncology First-in-Human Study: A Case of Roblitinib (FGF401)Mélanie Wilbaux, Shu Yang, Astrid Jullion, et al.
Gynecologic Oncology|April 15, 2014
Dynamic modeling in ovarian cancer: an original approach linking early changes in modeled longitudinal CA-125 kinetics and survival to help decisions in early drug developmentMélanie Wilbaux, Emilie Hénin, Amit Oza, et al.
Journal of Clinical Pharmacology|January 15, 2016
Pharmacometric Approaches to Personalize Use of Primarily Renally Eliminated Antibiotics in Preterm and Term NeonatesMélanie Wilbaux, Aline Fuchs, Janko Samardzic, et al.
Clinical Genitourinary Cancer|January 26, 2016
Identification of Most Aggressive Carcinoma Among Patients Diagnosed With Prostate Cancer Using Mathematical Modeling of Prostate-Specific Antigen IncreasesFélicité de Charry, Olivier Colomban, Benoit You, et al.
Clinical Nutrition (Edinburgh, Scotland)|April 29, 2018
Personalized weight change prediction in the first week of lifeMélanie Wilbaux, Severin Kasser, Julia Gromann, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Expert Review of Clinical Pharmacology|November 5, 2016
Pharmacometrics-based decision tools facilitate mHealth implementationFahima Nekka, Chantal Csajka, Mélanie Wilbaux, et al.
Expert Opinion on Drug Metabolism & Toxicology|January 29, 2016
Quantitative clinical pharmacology practice for optimal use of antibiotics during the neonatal periodJanko Samardzic, Karel Allegaert, Mélanie Wilbaux, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|December 16, 2016
Characterizing the dynamic interaction among gastric emptying, glucose absorption, and glycemic control in nondiabetic obese adultsMélanie Wilbaux, Bettina K Wölnerhanssen, Anne Christin Meyer-Gerspach, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 21, 2022
Contribution of machine learning to tumor growth inhibition modeling for hepatocellular carcinoma patients under Roblitinib (FGF401) drug treatmentMélanie Wilbaux, David Demanse, Yi Gu, et al.
The Journal of Pediatrics|April 4, 2016
Characterizing and Forecasting Individual Weight Changes in Term NeonatesMélanie Wilbaux, Severin Kasser, Sven Wellmann, et al.
Clinical Pharmacology and Therapeutics|September 22, 2022
Integration of Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy into Model-Informed Dose Selection in Oncology First-in-Human Study: A Case of Roblitinib (FGF401)Mélanie Wilbaux, Shu Yang, Astrid Jullion, et al.
Gynecologic Oncology|April 15, 2014
Dynamic modeling in ovarian cancer: an original approach linking early changes in modeled longitudinal CA-125 kinetics and survival to help decisions in early drug developmentMélanie Wilbaux, Emilie Hénin, Amit Oza, et al.
Journal of Clinical Pharmacology|January 15, 2016
Pharmacometric Approaches to Personalize Use of Primarily Renally Eliminated Antibiotics in Preterm and Term NeonatesMélanie Wilbaux, Aline Fuchs, Janko Samardzic, et al.
Clinical Genitourinary Cancer|January 26, 2016
Identification of Most Aggressive Carcinoma Among Patients Diagnosed With Prostate Cancer Using Mathematical Modeling of Prostate-Specific Antigen IncreasesFélicité de Charry, Olivier Colomban, Benoit You, et al.
Clinical Nutrition (Edinburgh, Scotland)|April 29, 2018
Personalized weight change prediction in the first week of lifeMélanie Wilbaux, Severin Kasser, Julia Gromann, et al.
Pageof 1